Genenta Science, which is engaged in the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, signed a development and manufacturing service agreement with AGC Biologics to manufacture cell therapy lentivirus-based product for Genenta’s ongoing clinical programs.
“The expansion of our existing relationship with AGC Biologics underscores the progress of our platform’s clinical development. Based on results from Phase I of the ongoing Phase I/II clinical trial, we are scaling up the manufacturing process to be ready for Phase II of the trial,” said Pierluigi Paracchi, CEO of Genenta. “This investment in manufacturing represents a significant step forward based on our expectation that our treatment has the potential to impact the tumor micro-environment and break immune tolerance in solid tumors.”
Genenta had an existing manufacturing services agreement with Molecular Medicine’s facility in Milan, which was subsequently acquired by AGC Biologics in 2020. The Milan site has been manufacturing lentiviral vectors and drug product for Genenta’s ongoing programs since 2016, starting with the initial process development steps. The services provided under this existing agreement are in addition to the services that will be provided under the AGC Biologics deal.
“This is the next step in our partnership with Genenta,” said Luca Alberici, general manager, AGC Biologics Milan. “This collaboration highlights the strength of AGC Biologics’ viral vector services, our scientific expertise, and the decades of scientific GMP manufacturing knowledge we have here in Milan.”
